title: Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.
abstract: The meningococcal groups C and Y and Haemophilus b (Hib) tetanus toxoid conjugate vaccine (HibMenCY-TT) contains Neisseria meningitidis serogroup C and Y capsular polysaccharide antigens, and Hib capsular polysaccharide [polyribosyl-ribitol-phosphate (PRP)]. The HibMenCY-TT vaccine is available in the USA for use as active immunization to prevent invasive disease caused by N. meningitidis serogroups C (MenC) and Y (MenY), and Hib in children 6 weeks-18 months of age. HibMenCY-TT is the first meningococcal vaccine available for use in the USA that can be administered to infants as young as 6 weeks of age. In a randomized, controlled, phase III clinical trial, the HibMenCY-TT vaccine, administered to infants at 2, 4, 6 and 12-15 months of age, was immunogenic against MenC and MenY, and met the prespecified criteria for immunogenicity. Anti-PRP antibodies, which have been shown to correlate with protection against Hib invasive disease, were also induced in the infants who received the HibMenCY-TT vaccine, with induced levels of this antibody noninferior to those occurring in the control group of infants who received a Hib tetanus toxoid conjugate vaccine at 2, 4, and 6 months and a single dose of Hib conjugated to N. meningitidis outer membrane protein at 12-15 months. In several randomized, controlled clinical trials, HibMenCY-TT was coadministered with vaccines that are routinely administered to infants and toddlers in the USA. These vaccines included: diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined; 7-valent Streptococcus pneumoniae polysaccharide conjugate vaccine; measles, mumps and rubella vaccine; and varicella vaccine. Coadministration of these vaccines did not interfere with the immunogenicity of the HibMenCY-TT vaccine. Similarly, immune responses to the coadministered vaccines were not affected by the HibMenCY-TT vaccine. The tolerability profile of the HibMenCY-TT vaccine in infants and toddlers in the phase III trial was considered to be clinically acceptable and comparable to that of the Hib conjugate vaccines received by the control group.
authors: Adis, 41 Centorian Drive Private Bag 65901 Mairangi Bay North Shore, 0754 Auckland, New Zealand. demail@springer.com
authors: Caroline M
authors: CM
authors: Perry
mesh_terms: D000367:Age Factors; D018073:Haemophilus Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D019741:Haemophilus influenzae type b / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D013745:Tetanus Toxoid / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D018074:Vaccines, Conjugate
chemical_list: D018073:Haemophilus Vaccines; C527605:Hib-MenCY-TT vaccine; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid; D017778:Vaccines, Combined; D018074:Vaccines, Conjugate
references: Expert Rev Vaccines. 2010 Mar;9(3):285-98
references: 20218857
references: Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S37-44
references: 20144015
references: Travel Med Infect Dis. 2010 Jan;8(1):47-50
references: 20188306
references: Clin Infect Dis. 2010 Jan 15;50(2):184-91
references: 20001736
references: Vaccine. 2007 Dec 12;25(51):8487-99
references: 17996996
references: J Infect Dis. 1984 Jun;149(6):1034-5
references: 6610714
references: Vaccine. 2011 Apr 18;29(18):3363-71
references: 21376800
references: Pediatrics. 1977 Nov;60(5):730-7
references: 335348
references: MMWR Morb Mortal Wkly Rep. 2013 Jan 25;62(3):52-4
references: 23344698
references: Expert Rev Vaccines. 2011 Jul;10(7):941-50
references: 21806393
references: J Exp Med. 1969 Jun 1;129(6):1307-26
references: 4977280
references: Adv Prev Med. 2011;2011:846756
references: 21991444
references: Hum Vaccin Immunother. 2012 Aug;8(8):1036-41
references: 22617844
references: J Infect Dis. 2000 Feb;181(2):761-4
references: 10669372
references: Clin Microbiol Rev. 2000 Jan;13(1):144-66, table of contents
references: 10627495
references: Pediatr Infect Dis J. 2013 Jun;32(6):662-8
references: 23340564
references: Hum Vaccin Immunother. 2012 Mar;8(3):304-11
references: 22327493
references: MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):72-6
references: 21270745
references: Hum Vaccin. 2010 Aug;6(8):640-51
references: 20697200
references: Pediatr Res. 1973 Mar;7(3):103-10
references: 4120458
references: Drugs. 2012 Dec 24;72(18):2407-30
references: 23231026
references: Pediatr Infect Dis J. 2011 Mar;30(3):190-6
references: 20948453
references: J Infect Dis. 1998 Sep;178(3):870-4
references: 9728562
references: Pediatr Infect Dis J. 2010 May;29(5):469-71
references: 20072077
references: Clin Microbiol Rev. 2006 Jan;19(1):142-64
references: 16418528
references: Pediatrics. 2011 Jun;127(6):e1375-85
references: 21624883
references: Vaccine. 2006 May 29;24(22):4692-700
references: 16621189
references: Clin Infect Dis. 2006 Jul 1;43(1):49-54
references: 16758417
references: Pediatr Infect Dis J. 2010 Jan;29(1):48-52
references: 20035207
references: Hum Vaccin. 2011 Feb;7(2):258-64
references: 21307655
references: Vaccine. 2007 Mar 1;25(11):1935-44
references: 17241707
references: J Infect Dis. 1983 Jun;147(6):1100
references: 6602191
references: Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
references: 19477562
references: J Travel Med. 2010 Sep-Oct;17 Suppl:3-8
references: 20849427